1,149
Views
0
CrossRef citations to date
0
Altmetric
Article

Gabapentin and oral antidepressants for chronic pruritus: a prospective cohort study evaluating efficacy and side effects in daily dermatological practice

ORCID Icon, &
Article: 2274291 | Received 31 Aug 2023, Accepted 10 Oct 2023, Published online: 31 Oct 2023

References

  • Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med. 2013;368(17):1–4. doi:10.1056/NEJMcp1208814.
  • Kopyciok ME, Stander HF, Osada N, et al. Prevalence and characteristics of pruritus: a one-week cross-sectional study in a German dermatology practice. Acta Derm Venereol. 2016;96(1):50–55. doi:10.2340/00015555-2166.
  • Weisshaar E, Szepietowski JC, Darsow U, et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92(5):563–581. doi:10.2340/00015555-1400.
  • Kim BS, Berger TG, Yosipovitch G. Chronic pruritus of unknown origin (CPUO): uniform nomenclature and diagnosis as a pathway to standardized understanding and treatment. J Am Acad Dermatol. 2019;81(5):1223–1224. doi:10.1016/j.jaad.2019.06.038.
  • Halvorsen JA, Dalgard F, Thoresen M, et al. Itch and mental distress: a cross-sectional study among late adolescents. Acta Derm Venereol. 2009;89(1):39–44. doi:10.2340/00015555-0554.
  • Dalgard F, Lien L, Dalen I. Itch in the community: associations with psychosocial factors among adults. J Eur Acad Dermatol Venereol. 2007;21(9):1215–1219. doi:10.1111/j.1468-3083.2007.02234.x.
  • Pereira MP, Stander S. Chronic pruritus: current and emerging treatment options. Drugs. 2017;77(9):999–1007. doi:10.1007/s40265-017-0746-9.
  • Stander S, Pogatzki-Zahn E, Stumpf A, et al. Facing the challenges of chronic pruritus: a report from a multi-disciplinary medical itch Centre in Germany. Acta Derm Venereol. 2015;95(3):266–271. doi:10.2340/00015555-1949.
  • Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99(5):469–506. doi:10.2340/00015555-3164.
  • Ständer S, Pereira MP, Berger T, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi:10.1097/itx.0000000000000042.
  • Stander S, Augustin M, Reich A, et al. Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) special interest group scoring itch in clinical trials. Acta Derm Venereol. 2013;93(5):509–514. doi:10.2340/00015555-1620.
  • Riepe C, Osada N, Reich A, et al. Minimal clinically important difference in chronic pruritus appears to be dependent on baseline itch severity. Acta Derm Venereol. 2019;99(13):1288–1290. doi:10.2340/00015555-3332.
  • Reich A, Riepe C, Anastasiadou Z, et al. Itch assessment with visual analogue scale and numerical rating scale: determination of minimal clinically important difference in chronic itch. Acta Derm Venereol. 2016;96(7):978–980. doi:10.2340/00015555-2433.
  • Park JM, Jwa SW, Song M, et al. Efficacy and safety of pregabalin for the treatment of chronic pruritus in Korea. J Dermatol. 2012;39(9):790–791. doi:10.1111/j.1346-8138.2012.01572.x.
  • Kouwenhoven TA, van de Kerkhof PCM, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: a systematic review. J Am Acad Dermatol. 2017;77(6):1068–1073 e7. doi:10.1016/j.jaad.2017.08.025.
  • Sreekantaswamy SA, Mollanazar N, Butler DC. Gabapentinoids for pruritus in older adults: a narrative review. Dermatol Ther (Heidelb). 2021;11(3):669–679. doi:10.1007/s13555-021-00513-z.
  • Roh YS, Khanna R, Patel SP, et al. Circulating blood eosinophils as a biomarker for variable clinical presentation and therapeutic response in patients with chronic pruritus of unknown origin. J Allergy Clin Immunol Pract. 2021;9(6):2513–2516 e2. doi:10.1016/j.jaip.2021.01.034.